{"id":"https://openalex.org/W2134855422","doi":"https://doi.org/10.1111/j.1463-1326.2011.01517.x","title":"Empagliflozin, a novel selective sodium glucose cotransporter\u20102 (SGLT\u20102) inhibitor: characterisation and comparison with other SGLT\u20102 inhibitors","display_name":"Empagliflozin, a novel selective sodium glucose cotransporter\u20102 (SGLT\u20102) inhibitor: characterisation and comparison with other SGLT\u20102 inhibitors","publication_year":2011,"publication_date":"2011-10-10","ids":{"openalex":"https://openalex.org/W2134855422","doi":"https://doi.org/10.1111/j.1463-1326.2011.01517.x","mag":"2134855422","pmid":"https://pubmed.ncbi.nlm.nih.gov/21985634"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2011.01517.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01517.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01517.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082492698","display_name":"Rolf Grempler","orcid":"https://orcid.org/0000-0002-9291-4947","observed_orcids":["https://orcid.org/0000-0002-9291-4947"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"R. Grempler","raw_affiliation_strings":["CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany. rolf.grempler@boehringer-ingelheim.com","Both authors contributed equally","CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany. rolf.grempler@boehringer-ingelheim.com","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Both authors contributed equally","institution_ids":[]},{"raw_affiliation_string":"CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061499869","display_name":"Leo H. Thomas","orcid":"https://orcid.org/0000-0002-2156-7298","observed_orcids":["https://orcid.org/0000-0002-2156-7298"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"L. Thomas","raw_affiliation_strings":["Both authors contributed equally","CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Both authors contributed equally","institution_ids":[]},{"raw_affiliation_string":"CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Eckhardt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"M. Eckhardt","raw_affiliation_strings":["Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075029211","display_name":"Frank Himmelsbach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"F. Himmelsbach","raw_affiliation_strings":["Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. Sauer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"A. Sauer","raw_affiliation_strings":["Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044147068","display_name":"Dale E. Sharp","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. E. Sharp","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031664049","display_name":"Remko A. Bakker","orcid":"https://orcid.org/0000-0003-1449-2862","observed_orcids":["https://orcid.org/0000-0003-1449-2862"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"R. A. Bakker","raw_affiliation_strings":["CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101439694","display_name":"Michael Mark","orcid":"https://orcid.org/0000-0002-8284-5773","observed_orcids":["https://orcid.org/0000-0002-8284-5773"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"M. Mark","raw_affiliation_strings":["CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032965517","display_name":"Thomas Klein","orcid":"https://orcid.org/0000-0001-5762-9166","observed_orcids":["https://orcid.org/0000-0001-5762-9166"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"T. Klein","raw_affiliation_strings":["CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062761332","display_name":"Peter Eickelmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"P. Eickelmann","raw_affiliation_strings":["CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5082492698"],"corresponding_institution_ids":["https://openalex.org/I1330995197"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":21.5679,"has_fulltext":false,"cited_by_count":625,"citation_normalized_percentile":{"value":0.99770382,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"14","issue":"1","first_page":"83","last_page":"90"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11140","display_name":"Natural Antidiabetic Agents Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":1.0},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9810000061988831},{"id":"https://openalex.org/keywords/sglt2","display_name":"SGLT2","score":0.9010000228881836},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9549999833106995},{"id":"https://openalex.org/keywords/binding-kinetics","display_name":"binding kinetics","score":0.5630000233650208},{"id":"https://openalex.org/keywords/competitive-inhibition","display_name":"competitive inhibition","score":0.5820000171661377},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.906000018119812},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.7710000276565552},{"id":"https://openalex.org/keywords/plasma-clearance","display_name":"plasma clearance","score":0.949999988079071},{"id":"https://openalex.org/keywords/species-differences","display_name":"species differences","score":0.6859999895095825},{"id":"https://openalex.org/keywords/zucker-diabetic-fatty-rats","display_name":"Zucker diabetic fatty rats","score":0.6179999709129333},{"id":"https://openalex.org/keywords/beagle","display_name":"beagle dogs","score":0.8259999752044678},{"id":"https://openalex.org/keywords/myo-inositol-uptake","display_name":"myo-inositol uptake","score":0.9589999914169312}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.9948710203170776},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.677013099193573},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6298686265945435},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6291048526763916},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.47761791944503784},{"id":"https://openalex.org/C2777451236","wikidata":"https://www.wikidata.org/wiki/Q5030940","display_name":"Canagliflozin","level":4,"score":0.4575450122356415},{"id":"https://openalex.org/C2776820430","wikidata":"https://www.wikidata.org/wiki/Q21102","display_name":"Beagle","level":2,"score":0.45375585556030273},{"id":"https://openalex.org/C150757390","wikidata":"https://www.wikidata.org/wiki/Q1985205","display_name":"Non-competitive inhibition","level":3,"score":0.445195734500885},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.35876980423927307},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.2818223834037781},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2708919644355774},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.25997185707092285},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2491379678249359},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.19764098525047302},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.057433128356933594},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004285","descriptor_name":"Dogs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D009004","descriptor_name":"Monosaccharide Transport Proteins","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009004","descriptor_name":"Monosaccharide Transport Proteins","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D011924","descriptor_name":"Rats, Zucker","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2011.01517.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01517.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01517.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:21985634","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21985634","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320306257","display_name":"Boehringer Ingelheim","ror":"https://ror.org/05kffp613"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W70305309","https://openalex.org/W159658320","https://openalex.org/W201601384","https://openalex.org/W1969979801","https://openalex.org/W1984700778","https://openalex.org/W1990462691","https://openalex.org/W1992070954","https://openalex.org/W1996143753","https://openalex.org/W2014560547","https://openalex.org/W2026609170","https://openalex.org/W2040687831","https://openalex.org/W2050614267","https://openalex.org/W2051728893","https://openalex.org/W2069496858","https://openalex.org/W2078992128","https://openalex.org/W2080449229","https://openalex.org/W2086812198","https://openalex.org/W2090088543","https://openalex.org/W2103869657","https://openalex.org/W2106340518","https://openalex.org/W2126255509","https://openalex.org/W2126759884","https://openalex.org/W2127833912","https://openalex.org/W2132693290","https://openalex.org/W2142360957","https://openalex.org/W2144173715","https://openalex.org/W2149185387","https://openalex.org/W2158811015","https://openalex.org/W2159651456","https://openalex.org/W2169214766","https://openalex.org/W2170276146","https://openalex.org/W2171786511"],"related_works":["https://openalex.org/W2919894951","https://openalex.org/W2621023143","https://openalex.org/W2140411181","https://openalex.org/W7099507499","https://openalex.org/W7166729497","https://openalex.org/W2287058651","https://openalex.org/W2123655868","https://openalex.org/W2069845056","https://openalex.org/W2171786511","https://openalex.org/W2044904729"],"abstract_inverted_index":{"AIMS:":[0],"Empagliflozin":[1,116,162,190,215],"is":[2,129,191],"a":[3,86,144,192],"selective":[4],"sodium":[5],"glucose":[6,132],"cotransporter-2":[7],"(SGLT-2)":[8],"inhibitor":[9,197],"in":[10,28,33,98,157,164,179],"clinical":[11],"development":[12],"for":[13,123],"the":[14,204,209],"treatment":[15],"of":[16,26,101,120,147,208],"type":[17],"2":[18,61],"diabetes":[19],"mellitus.":[20],"This":[21],"study":[22],"assessed":[23],"pharmacological":[24],"properties":[25,32],"empagliflozin":[27,92,142],"vitro":[29],"and":[30,35,39,62,70,74,76,93,109,153,175,185,194,203],"pharmacokinetic":[31],"vivo":[34,99],"compared":[36],"its":[37],"potency":[38],"selectivity":[40,148,159,201,206],"with":[41,53,90,105,131,138,198],"other":[42,139],"SGLT-2":[43,128,140,196,211],"inhibitors.":[44],"METHODS:":[45],"[(14)C]-alpha-methyl":[46],"glucopyranoside":[47],"(AMG)":[48],"uptake":[49,78],"experiments":[50],"were":[51,72,83,160,167],"performed":[52,104],"stable":[54],"cell":[55,66,95],"lines":[56,67],"over-expressing":[57,68],"human":[58],"(h)":[59],"SGLT-1,":[60,150],"4.":[63],"Two":[64],"new":[65],"hSGLT-5":[69],"hSGLT-6":[71],"established":[73],"[(14)C]-mannose":[75],"[(14)C]-myo-inositol":[77],"assays":[79],"developed.":[80],"Binding":[81],"kinetics":[82],"analysed":[84],"using":[85],"radioligand":[87],"binding":[88,126],"assay":[89],"[(3)H]-labelled":[91],"HEK293-hSGLT-2":[94],"membranes.":[96],"Acute":[97],"assessment":[100],"pharmacokinetics":[102,163],"was":[103,183,187],"normoglycaemic":[106],"beagle":[107,180],"dogs":[108,181],"Zucker":[110],"diabetic":[111],"fatty":[112],"(ZDF)":[113],"rats.":[114],"RESULTS:":[115],"has":[117,143],"an":[118,199,217],"IC(50)":[119],"3.1":[121],"nM":[122],"hSGLT-2.":[124],"Its":[125],"to":[127,221],"competitive":[130,195],"(half-life":[133],"approximately":[134],"1":[135],"h).":[136],"Compared":[137],"inhibitors,":[141],"high":[145],"degree":[146],"over":[149,213],"4,":[151],"5":[152],"6.":[154],"Species":[155],"differences":[156],"SGLT-1":[158],"identified.":[161],"ZDF":[165],"rats":[166],"characterised":[168],"by":[169],"moderate":[170],"total":[171],"plasma":[172],"clearance":[173],"(CL)":[174],"bioavailability":[176],"(BA),":[177],"while":[178],"CL":[182],"low":[184],"BA":[186],"high.":[188],"CONCLUSIONS:":[189],"potent":[193],"excellent":[200],"profile":[202],"highest":[205],"window":[207],"tested":[210],"inhibitors":[212],"hSGLT-1.":[214],"represents":[216],"innovative":[218],"therapeutic":[219],"approach":[220],"treat":[222],"diabetes.":[223]},"counts_by_year":[{"year":2026,"cited_by_count":34},{"year":2025,"cited_by_count":38},{"year":2024,"cited_by_count":38},{"year":2023,"cited_by_count":39},{"year":2022,"cited_by_count":53},{"year":2021,"cited_by_count":46},{"year":2020,"cited_by_count":53},{"year":2019,"cited_by_count":45},{"year":2018,"cited_by_count":35},{"year":2017,"cited_by_count":46},{"year":2016,"cited_by_count":45},{"year":2015,"cited_by_count":48},{"year":2014,"cited_by_count":49},{"year":2013,"cited_by_count":39},{"year":2012,"cited_by_count":13}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}